Zacks: Brokerages Anticipate Kitov Pharmaceuticals Holdings Ltd (KTOV) to Announce -$0.01 EPS

Brokerages predict that Kitov Pharmaceuticals Holdings Ltd (NASDAQ:KTOV) will announce ($0.01) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Kitov Pharmaceuticals’ earnings. The company is scheduled to announce its next earnings report on Monday, May 7th.

On average, analysts expect that Kitov Pharmaceuticals will report full year earnings of ($0.01) per share for the current year. Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Kitov Pharmaceuticals.

Separately, HC Wainwright raised shares of Kitov Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $10.00 price target for the company in a report on Tuesday, November 21st.

Kitov Pharmaceuticals (NASDAQ KTOV) opened at $2.55 on Monday. Kitov Pharmaceuticals has a 1-year low of $1.27 and a 1-year high of $3.44.

TRADEMARK VIOLATION NOTICE: This report was posted by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at

About Kitov Pharmaceuticals

Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.

Get a free copy of the Zacks research report on Kitov Pharmaceuticals (KTOV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Kitov Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kitov Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply